Commentary: Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.

Front Oncol

Department of Laboratory Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang, Jiangsu, China.

Published: September 2024

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459067PMC
http://dx.doi.org/10.3389/fonc.2024.1417921DOI Listing

Publication Analysis

Top Keywords

commentary serum
4
serum ezh2
4
ezh2 novel
4
novel biomarker
4
biomarker bladder
4
bladder cancer
4
cancer diagnosis
4
diagnosis prognosis
4
commentary
1
ezh2
1

Similar Publications

Marburg virus disease outbreak in Rwanda, 2024.

Clin Microbiol Infect

November 2024

Emerging Infections Subcommittee, European Society of Clinical Microbiology and Infectious Disease, Switzerland; High-Level Isolation Unit, Infectious Diseases Unit, La Paz University Hospital, IdiPAZ, CIBERINFEC, Madrid, Spain.

View Article and Find Full Text PDF

This editorial offers commentary on the article which aimed to forecast the likelihood of short-term major postoperative complications (Clavien-Dindo grade ≥ III), including anastomotic fistula, intra-abdominal sepsis, bleeding, and intestinal obstruction within 30 days, as well as prolonged hospital stays following ileocecal resection in patients with Crohn's disease (CD). This prediction relied on a machine learning (ML) model trained on a cohort that integrated a nomogram predictive model derived from logistic regression analysis and a random forest (RF) model. Both the nomogram and RF showed good performance, with the RF model demonstrating superior predictive ability.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!